Analyst Price Targets — ALEC
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| October 22, 2025 1:05 pm | — | H.C. Wainwright | $5.00 | $3.21 | TheFly | Alector price target lowered to $5 from $10 at H.C. Wainwright |
| October 22, 2025 8:38 am | — | Mizuho Securities | $1.50 | $3.21 | TheFly | Alector downgraded to Neutral from Outperform at Mizuho |
| November 19, 2024 9:07 pm | Corinne Jenkins | Goldman Sachs | $4.00 | $5.08 | StreetInsider | Goldman Sachs Reiterates Sell Rating on Alector Inc. (ALEC) |
Latest News for ALEC
After reaching an important support level, Alector, Inc. (ALEC) could be a good stock pick from a technical perspective. ALEC recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
Three health-technology names are drawing fresh analyst attention this week as strategic partnerships and business pivots reframe the risk-reward calculus for each.
Alector, Inc. (ALEC) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Alector (ALEC) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to a loss of $0.02 per share a year ago.
Advancing the Alector Brain Carrier (ABC) platform across multiple therapeutic modalities, including antibodies, enzymes, and siRNA, with continued progress across AL137 (ABC-enabled anti-amyloid antibody for Alzheimer's Disease), AL050 (ABC-enabled GCase Enzyme Replacement Therapy for Parkinson's Disease) and AL064 (ABC-enabled Tau siRNA for Alzheimer's Disease) Independent interim futility analysis of the…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ALEC.
U.S. House Trading
No House trades found for ALEC.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.